B7H3 (CD276) Human shRNA Plasmid Kit (Locus ID 80381)
CAT#: TR317545
CD276 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector, 5µg of each construct provided
Need custom shRNA service?
Get a free quote
CNY 4,790.00
货期*
现货
规格
Cited in 1 publication. |
Product images
经常一起买 (2)
CD276 mouse monoclonal antibody, clone OTI1A10
CNY 1,999.00
CNY 3,600.00
Specifications
Product Data | |
Product Name | B7H3 (CD276) Human shRNA Plasmid Kit (Locus ID 80381) |
Locus ID | 80381 |
UniProt ID | Q5ZPR3 |
Synonyms | 4Ig-B7-H3; B7-H3; B7H3; B7RP-2 |
Vector | pRS |
Format | Retroviral plasmids |
Kit Components | CD276 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID = 80381). 5µg purified plasmid DNA per construct29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free. |
RefSeq | BC011578, NM_001024736, NM_025240, NM_001329628, NM_001329629, NM_001024736.1, NM_025240.1, NM_025240.2, BC062581, NM_001024736.2 |
Summary | The protein encoded by this gene belongs to the immunoglobulin superfamily, and thought to participate in the regulation of T-cell-mediated immune response. Studies show that while the transcript of this gene is ubiquitously expressed in normal tissues and solid tumors, the protein is preferentially expressed only in tumor tissues. Additionally, it was observed that the 3' UTR of this transcript contains a target site for miR29 microRNA, and there is an inverse correlation between the expression of this protein and miR29 levels, suggesting regulation of expression of this gene product by miR29. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Sep 2011] |
shRNA Design | These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service. |
Performance Guaranteed | OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples. For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred). |
Citations (1)
The use of this RNAi has been cited in the following citations: |
---|
Role of MYC-miR-29-B7-H3 in Medulloblastoma Growth and Angiogenesis
,Purvis, IJ;Avilala, J;Guda, MR;Venkataraman, S;Vibhakar, R;Tsung, AJ;Velpula, KK;Asuthkar, S;,
J Clin Med
,PubMed ID 31382461
[CD276]
|
Documents
Product Manuals |
FAQs |
SDS |
Customer
Reviews
Loading...